Response to Comments: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis

This document is a response to comments on the MolDX Local Coverage Determination for molecular testing related to hereditary transthyretin (TTR) amyloidosis and does not include clinical coverage criteria. It provides administrative timeline details: comment period 2024-08-29 to 2024-10-12, notice period 2025-07-03 to 2025-08-16, with an effective date of 2025-08-17.